304 related articles for article (PubMed ID: 25630643)
1. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of HIV integrase inhibitors.
Adams JL; Greener BN; Kashuba AD
Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
Elliot E; Amara A; Jackson A; Moyle G; Else L; Khoo S; Back D; Owen A; Boffito M
J Antimicrob Chemother; 2016 Apr; 71(4):1031-6. PubMed ID: 26679246
[TBL] [Abstract][Full Text] [Related]
6. Next-generation integrase inhibitors : where to after raltegravir?
Karmon SL; Markowitz M
Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
8. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
[No Abstract] [Full Text] [Related]
9. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
11. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
12. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Cattaneo D; Minisci D; Baldelli S; Mazzali C; Giacomelli A; Milazzo L; Meraviglia P; Resnati C; Rizzardini G; Clementi E; Galli M; Gervasoni C
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):86-92. PubMed ID: 28961682
[TBL] [Abstract][Full Text] [Related]
15. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir.
Jain P; Thota A; Saini PK; Raghuvanshi RS
Crit Rev Anal Chem; 2024; 54(2):401-415. PubMed ID: 35617468
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
Cottrell ML; Hadzic T; Kashuba AD
Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]